This first-in-human trial evaluates safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-514 as monotherapy and in combination with budigalimab (BDG), a PD-1–blocking antibody.

2024年10月24日 · ABBV-514 is an anti-chemokine C-C motif receptor 8 (CCR8) antibody that is being investigated for the treatment of relapsed non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in …

ABBV-514 is an afucosylated monoclonal antibody that binds CCR8 and is designed to enhance antibody-dependent cellular cytotoxicity to deplete tumor-in ltrating Tregs.This rst-in-human trial evaluates safety, pharmacokinetics (PK), and fi fi preliminary ef cacy of ABBV-514 as monotherapy and in combination with budiga-fi limab (BDG), a PD ...

In dose expansion, patients with R/R non-small cell lung cancer will be enrolled in ABBV-514 monotherapy (N=12) and ABBV-514 + BDG (N=12) cohorts, and patients with R/R head and neck squamous cell carcinoma in an ABBV-514 + BDG (N=12) cohort. Enrollment initiated in November 2021, with 30 patients enrolled as of April 2023.

Budigalimab and ABBV-514 are investigational drugs being developed for the treatment of NSCLC, HNSCC, and other solid tumors. Study doctors put the participants in groups called treatment arms. The maximum-tolerated dose (MTD)/maximum administered dose (MAD) of ABBV-514 will be explored.

This first-in-human study evaluates the safety, pharmacology, and preliminary eficacy of ABBV-514 as monotherapy and in combination with budigalimab, a programmed cell death protein 1 (PD-1) inhibitor, in patients with locally advanced or metastatic solid tumors

Budigalimab and ABBV-514 are investigational drugs being developed for the treatment of NSCLC, HNSCC, and other solid tumors. Study doctors put the participants in groups called treatment arms. The maximum-tolerated dose (MTD)/maximum administered dose (MAD) of ABBV-514 will be explored.

CCR8-targeted Treg depletion and PD-1 blockade combine to divert CD8+ T cells from exhaustion associated transcriptional trajectories within the tumor microenvironment (SITC 2024) - P1 | "A human CCR8 specific afucosylated IgG1 antibody (ABBV-514) is currently being evaluated in a Phase I clinical trial both as monotherapy and in combination ...

2021年8月12日 · Budigalimab and ABBV-514 are investigational drugs being developed for the treatment of NSCLC, HNSCC, and other solid tumors. Study doctors put the participants in groups called treatment arms. The maximum-tolerated dose (MTD)/maximum administered dose (MAD) of ABBV-514 will be explored.

この試験は、標準治療後の進行性固形がんを対象にした第I相の臨床試験で、抗CCR-8抗体の単剤または抗PD-1抗体との併用療法を投与する臨床試験です。 注：上記の患者選択基準は概要であり、上記に該当していてもこの治験に参加できないことがありますので、ご了承ください。 注：この治験に参加した患者さんは、単剤療法、併用療法のいずれかを受けることになります。 ご自分で選択することは出来ません. 治験薬は製薬企業から無償提供されますが、それ以外の …